AKRO241220C45000
- 0.00
- 0.000.00%
Akero Therapeutics Newsroom
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
Akero a New Buy at Citi on Liver Disease Asset
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup
Promising Potential of Akero Therapeutics' Efruxifermin Highlighted by Positive Phase 2b HARMONY Study Results
Akero Therapeutics (AKRO) Receives a Buy From Phillip Securities
Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics
Akero Therapeutics Reports Positive Results for Efruxifermin in Treating Metabolic Dysfunction-Associated Steatohepatitis at AASLD Liver Meeting 2024
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting 2024
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
BofA Securities Initiates Akero Therapeutics(AKRO.US) With Hold Rating
Bank of America Securities Reaffirms Their Hold Rating on Akero Therapeutics (AKRO)
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Akero Therapeutics Advances in MASH Treatment Trials
Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Akero Therapeutics Analyst Ratings
Positive Outlook for Akero Therapeutics Driven by Efruxifermin's Potential and Strategic Clinical Programs
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46